Concepedia

Michael Storek

MS

Statistics

Publications

20

Citations

747

H-Index

15

Active since

2002

Affiliations

Sanofi (United States)(Current)

Alexion Pharmaceuticals (United States)

Sanofi (France)

University of Colorado Denver

Harvard University

Michael Storek is an author at Sanofi (United States) specializing in complement system, life sciences, and complement-targeted therapy.

Publications per year

2002–2024

20

Publications

20

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis‐Hareli, Michael Storek, István Mazsaroff et al. · Blood · 2011 · 118 citations · Full text

, , +11

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini et al. · Blood · 2022 · 115 citations · Full text

, , +17

Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2

Roni Mamluk, Irvith M. Carvajal, Brent Morse et al. · mAbs · 2010 · 80 citations · Full text

, , +15

Classical Complement Pathway Inhibition in a “Human‐On‐A‐Chip” Model of Autoimmune Demyelinating Neuropathies

John W. Rumsey, Case Lorance, Max Jackson et al. · Advanced Therapeutics · 2022 · 74 citations · Full text

, , +17

Dicamba Monooxygenase: Structural Insights into a Dynamic Rieske Oxygenase that Catalyzes an Exocyclic Monooxygenation

Robert L. D’Ordine, T.J. Rydel, Michael Storek et al. · Journal of Molecular Biology · 2009 · 65 citations

, , +13

1–5 of 20